Wound-surface extracellular matrix proteins and platelets

Wound-surface extracellular matrix proteins and platelets represent a composite therapeutic target primarily addressed by topical hemostatic agents and surgical sealants. Upon tissue injury, the exposure of extracellular matrix (ECM) components, such as collagen and von Willebrand factor, initiates the natural hemostatic process by providing a surface for platelet attachment and activation (StatPearls, 2023). Therapeutic products targeting this interface, such as fibrin sealants (e.g., TachoSil), deliver concentrated fibrinogen and thrombin directly to the wound site. These components react to form a cross-linked fibrin clot that integrates with the host's ECM and incorporates local platelets, effectively sealing the wound and stopping hemorrhage (AdisInsight, 2024). This target is particularly relevant in surgical procedures where traditional methods of hemostasis are insufficient or where rapid sealing of air or fluid leaks is required. Safety concerns include the risk of thromboembolic events if the agents enter the systemic circulation and potential hypersensitivity to human or animal-derived proteins (FDA, TachoSil Label).

Other names

Extracellular matrixPlateletsWound bedExposed collagenFibrinogen-thrombin target surface

Topical hemostatic agents interact with this target by providing exogenous coagulation factors (thrombin and fibrinogen) that react upon contact with the wound surface. Thrombin converts fibrinogen into fibrin, which polymerizes to form a mesh that physically adheres to exposed extracellular matrix proteins (like collagen) and traps platelets, creating a stable physiological seal (StatPearls, 2023; AdisInsight, 2024).